Overview

Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori

Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in triple therapy. This study explores a non-antibiotic treatment regime for H.pylori that uses lauric acid as the primary anti-microbial agent. The study hypothesis is that Lauric acid works synergistically with omeprazole following administration of a mucolytic agent to kill H.pylori topically in the stomach.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Synergy Pharmaceuticals Pte. Ltd.
Collaborator:
Singapore General Hospital
Treatments:
Omeprazole